Publication:
Serum IL-23 levels in patients with vitiligo

Simple item page
dc.contributor.authorCengiz, FATMA PELİN
dc.contributor.authorEmiroglu, NAZAN
dc.contributor.authorCEMIL, Bengu Cevirgen
dc.contributor.authorERDEM, Ummu Gul Bahar
dc.contributor.authorKEMERIZ, Funda
dc.contributor.institutionauthorCENGİZ, FATMA PELIN
dc.contributor.institutionauthorEMİROĞLU, NAZAN
dc.date.accessioned2020-10-30T00:02:12Z
dc.date.available2020-10-30T00:02:12Z
dc.date.issued2014-12-01T00:00:00Z
dc.description.abstractBackground and Design: Interleukin-23 (IL-23) is a cytokine which is believed to have an important role in the pathogenesis of autoimmune diseases. Therefore, it can be used as a target molecule in the treatment of autoimmune diseases. The aim of our study was to determine serum IL-23 levels in patients with vitiligo to understand their possible roles in the disease etiology and to compare the results with the healthy controls.
dc.identifier.citationCengiz F. P. , Emiroglu N., CEMIL B. C. , ERDEM U. G. B. , KEMERIZ F., -Serum IL-23 levels in patients with vitiligo-, TURKDERM-ARCHIVES OF THE TURKISH DERMATOLOGY AND VENEROLOGY, cilt.48, ss.204-207, 2014
dc.identifier.doi10.4274/turkderm.82957
dc.identifier.scopus84921821140
dc.identifier.urihttp://hdl.handle.net/20.500.12645/27095
dc.identifier.wosWOS:000348823600008
dc.titleSerum IL-23 levels in patients with vitiligo
dc.typeArticle
dspace.entity.typePublication
local.avesis.ide8569eee-927f-4285-bc34-a7eadc311a38
local.publication.isinternational1
relation.isAuthorOfPublication292e9ebe-735f-4346-90cf-5e0d8d0ed89d
relation.isAuthorOfPublication59744f77-dd5d-4ff4-964f-0bb4780aaac6
relation.isAuthorOfPublication.latestForDiscovery292e9ebe-735f-4346-90cf-5e0d8d0ed89d
Files
Collections
Silinecekler